Physician profile
Anna Janicki
NPI 1528187481
$1,812.22
in general payments reported to CMS, 2019-2025
17 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $14.24 · 2021: $45.27 · 2022: $234 · 2023: $311 · 2024: $624 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $279.93 | 2019-2025 | Rexulti |
| Lundbeck LLC | $270.06 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.98 | 2022-2025 | Caplyta |
| Abbvie INC. | $188.40 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $172.71 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $159.95 | 2021-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $141.47 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $75.74 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $70.18 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $50.14 | 2019-2025 | Trintellix |
| Alkermes, INC. | $49.17 | 2023-2024 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $47.02 | 2024-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $32.44 | 2024 | Hetlioz, Fanapt |
| Corium, LLC | $22.23 | 2024 | Azstarys |
| Shire North American Group INC | $15.68 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.08 | 2022 | |
| Neuronetics, INC. | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Janicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.